Targeting Mast Cells: A New Frontier in Allergy & Inflammation with Jasper Therapeutics’ CMO Dr. Edwin Tucker

Xtalks Life Science Podcast

In this episode of the Xtalks Life Science Podcast, host Ayesha Rashid speaks with Edwin Tucker, MD, MBA, Chief Medical Officer (CMO) at Jasper Therapeutics, about innovative approaches to treating chronic mast cell diseases such as asthma, food allergies and IBS.

Dr. Tucker has over 30 years of clinical drug development experience, with past roles as CMO at Goldfinch Bio and Mirum Pharmaceuticals, where he led the first FDA approval for Alagille Syndrome. He also served as COO at Acerta Pharma and held leadership positions at Genentech, Janssen and Bayer.

Dr. Tucker is a member of the Royal College of Physicians (UK). He received his MBA from the University of Connecticut and holds degrees in Pharmacology and Medicine from the University of Leeds, UK. Additionally, he serves as a managing director at Golden Seeds, an investment firm dedicated to pursuing early-stage investment opportunities in women-led businesses.

Tune in to learn how Jasper Therapeutics’ work could reshape the landscape for patients with allergic and inflammatory conditions.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured